GlassScriptPhysician profile
Samuel Szumstein
NPI 1790783603
$10,009.38
in general payments reported to CMS, 2019-2025
46 companies · $2,130 in 2025
The $2,130 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,139 · 2020: $1,077 · 2021: $997 · 2022: $1,503 · 2023: $1,636 · 2024: $1,526 · 2025: $2,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,080 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,080.31 |
| Education | $211.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $1,346.58 | 2020-2025 | Wakix |
| Glaxosmithkline, LLC. | $1,163.38 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Jazz Pharmaceuticals INC. | $907.07 | 2019-2025 | Xywav |
| Astrazeneca Pharmaceuticals LP | $740.53 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $696.31 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $503.93 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Inspire Medical Systems, INC. | $489.82 | 2019-2025 | Inspire |
| Axsome Therapeutics, INC. | $477.32 | 2022-2025 | Sunosi |
| Genzyme Corporation | $384.44 | 2019-2025 | |
| Zoll Respicardia, INC. | $342.46 | 2019-2024 | Remede System |
| Takeda Pharmaceuticals U.S.A., INC. | $252.11 | 2022-2025 | Cuvitru, Glassia, Hyqvia |
| Mylan Specialty L.P. | $248.00 | 2019-2024 | Yupelri |
| Insmed, INC. | $232.77 | 2020-2025 | Arikayce, Brinsupri |
| Pfizer INC. | $204.61 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $170.43 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Szumstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.